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Reduced gene expression of adiponectin in fat tissue from pa-
tients with end-stage renal disease.
Background. Cardiovascular disease (CVD) is the main
cause of death in end-stage renal disease (ESRD) patients. It
has been suggested that inflammation plays a key role in the de-
velopment of both atherosclerosis and malnutrition (MIA), a
combination of complications associated with poor outcome.
Although plasma levels of adiponectin, a recently discov-
ered anti-inflammatory and antiatherogenic adipocytokine, are
markedly elevated in ESRD, gene expression of adiponectin
(ApM1) has not been analyzed in ESRD patients.
Methods. We analyzed the ApM1 gene expression in adipose
tissue from 18 ESRD patients of whom 9 (7 males, 60 ± 8 years,
BMI 24 ± 6 kg/m2) had a high prevalence of MIA complications,
and 9 age- (55 ± 9 years), gender- (7 males) and BMI- (24 ±
2 kg/m2) matched ESRD patients had few MIA complications.
The results were compared with age- (59 ± 11 years), gender-
(7 males), and BMI- (24 ± 6 kg/m2) matched healthy control
patients. Information on CVD was obtained at the recruitment
based on a detailed medical history. Malnutrition was defined as
a subjective global assessment (SGA) score >1. Inflammation
was defined as CRP ≥10 mg/L. Gene expression analysis was
performed using the in situ hybridization technique.
Results. Gene expression of ApM1 was lower in ESRD pa-
tients compared with healthy control patients (P = 0.001). On
the other hand, when comparing the gene expression between
ESRD patients with and without MIA complications, respec-
tively, no difference in the ApM1 gene expression was detected.
Conclusion. Adiponectin gene expression is significantly
down-regulated in ESRD patients compared with healthy con-
trol patients. We propose that the decrease in expression may
be the result of a negative feedback regulation, as a result of el-
evated levels of circulating adiponectin caused by renal failure.
Premature death from cardiovascular disease (CVD)
accounts for more than 50% of the mortality in patients
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with end-stage renal disease (ESRD) [1]. Although tra-
ditional risk factors, such as hypertension, diabetes melli-
tus, and dyslipidemia, may account for a large portion of
premature CVD, they cannot alone fully account for the
unacceptable high cardiovascular mortality rate in this
patient population. Thus, much recent interest has fo-
cused on nontraditional risk factors, such as inflam-
mation, malnutrition, oxidative stress, and endothelial
dysfunction. It is noticeable that strong associations ex-
ist between the presence of inflammation, malnutrition,
and atherosclerosis (MIA) in ESRD [2], and it has been
suggested that inflammation and oxidative stress may in
concert with endothelial dysfunction, mediate acceler-
ated atherosclerosis in ESRD [3].
Adipose tissue has recently been considered to be
a hormonally active system that, among a number of
other proteins, secretes a newly detected adipocytokine,
adiponectin, which may have anti-inflammatory and an-
tiatherosclerotic properties [4, 5] because of its modula-
tory effects on the endothelial inflammatory response in
vitro [5]. Adiponectin is an adipose tissue–specific 244
amino acid protein discovered in 1996 [6, 7], also re-
ferred to as gelatin-binding protein [6]. The function(s)
of this protein are not yet fully established. However, it
has been suggested that adiponectin has an antiathero-
genic effect because it inhibits monocyte adhesion to
endothelial cells and macrophage-to-foam cell transfor-
mation, thereby modulating the inflammatory response
of endothelial cells in vascular injury [8]. It has also been
reported that adiponectin suppresses tumor necrosis fac-
tor (TNF)-a–induced nuclear factor (NF)-jB activation
in human aortic endothelial cells [4].
Adiponectin circulates at high levels in human plasma,
ranging from 2 to 20 mg/L, constituting 0.01% of the total
plasma protein pool [9]. The gene encoding adiponectin,
ApM1 (adipose most abundant gene transcript 1), is lo-
cated in a diabetes susceptibility locus on chromosome
3q27 [10]. Although other patient groups with increased
risk of CVD, such as patients with dyslipidemia [11],
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essential hypertension [12, 13], type 2 diabetes mellitus
[14], obesity [9], and coronary artery disease [15] have
decreased adiponectin levels, markedly elevated plasma
adiponectin levels have been demonstrated in ESRD pa-
tients [16, 17]. However, although higher than in control
patients, Zoccali et al [16] found that low circulating
plasma levels of adiponectin predicted cardiovascular
events also in ESRD patients. Previous studies in non-
renal patient groups with increased risk of CVD have
shown that gene expression of adiponectin is significantly
decreased [18]. However, to the best of our knowledge,
the ApM1 gene expression has not yet been analyzed in
ESRD patients.
The aim of this study was therefore to investigate the
ApM1gene expression in ESRD patients in comparison
to age-, gender- and BMI-matched control patients. We
measured the expression of the ApM1 gene in adipose
tissue from ESRD patients with a high and low preva-
lence of malnutrition, inflammation, and atherosclerotic
cardiovascular disease (MIA), as well as in healthy con-
trol patients.
METHODS
Study subjects
The patients were recruited shortly before the initi-
ation of renal replacement therapy. The glomerular fil-
tration rate (GFR) was estimated by the mean of urea
and creatinine clearances. Patients were divided into two
groups according to the presence of malnutrition, in-
flammation, and atherosclerotic cardiovascular disease
(MIA) parameters (Table 1). Information on clinical
CVD (coronary artery disease, cerebrovascular disease,
and peripheral artery disease) was obtained at the recruit-
ment from a detailed medical history. Malnutrition was
defined as a subjective global assessment (SGA) score
>1, as previously described [2], and inflammation as C-
reactive protein (CRP) levels≥10 mg/L. All patients were
free of clinically overt infectious complications at the time
of the study. Nine patients (7 males; 60 ± 8 years; BMI 24
± 2 kg/m2) with 2 or 3 of the MIA complications were in-
cluded in the MIA ESRD group, while 9 ESRD patients
with no, or one, complication were included in the non-
MIA ESRD group. In the MIA ESRD patient group, 6
had diabetes mellitus (DM; 4 type 1 DM), 1 had polycys-
tic kidney disease, 1 a postrenal etiology of ESRD, and 1
had chronic renal disease of unknown origin. In the non-
MIA ESRD group (7 males, 2 females), the mean age was
55 ± 9 years (BMI 24 ± 6 kg/m2). One patient had type
1 DM, 2 had polycystic kidney disease, and 6 had chronic
glomerulonephritis. The 9 healthy control patients con-
sisted of a matched group (7 males; age 59±11 years; BMI
24 ± 6 kg/m2) undergoing elective laparoscopic cholecys-
tectomy (but otherwise healthy) at Huddinge University
Hospital. All 3 groups were matched for age, gender, and
BMI. The Ethics Committee of Karolinska Institutet ap-
proved the study protocol at Huddinge University Hospi-
tal, Stockholm, and informed consent was obtained from
all subjects.
Adipose tissue biopsies
The ESRD patients fasted overnight. After local anes-
thesia, biopsies were taken from the abdominal subcu-
taneous adipose tissue for determination of ApM1 gene
expression. In healthy control patients, consisting of oth-
erwise healthy subjects undergoing elective laparoscopic
cholecystectomy, abdominal fat biopsies were taken af-
ter general anesthesia. General anesthesia was induced
at 8 a.m. by a short-acting barbiturate, and maintained by
fentanyl and a mixture of oxygen and nitrous oxide. In-
travenous saline was administered before taking biopsies
from the abdominal adipose tissue. The adipose tissue
specimens ranged from 200 to 1000 mg, and were imme-
diately frozen unfixed on dry ice in the operating room
and stored at −70◦C until sectioned.
Tissue preparation and probe labeling
The fat tissue biopsies were cut to a thickness of 14
lm in a cryostat (CM 3000; Leica Instruments GmbH,
Nussloch, Germany) at −35◦C to −40◦C, and thawed
onto electrically charged PolysineTM microscope slides
(Menzel-Gla¨ser, Braunschweig, Germany). The slides
were thereafter processed for in situ hybridization. The
probes, ApM1 sense, ApM1 anti-sense, gamma-actin,
and cholecystokinin (CCK), were labeled by mixing 2 lL
oligonucleotide (40 ng/lL), 1.5 lL 5 × TdT (Amersham
Pharmacia Biotech, Inc., Piscataway, NJ, USA), 3 lL
distilled H2O, 6 lL 33P (NEG/312H; Perkin Elmer Life
Sciences, Inc., Boston, MA, USA), and the reaction
volume was incubated for 1 hour at 37◦C. The labeled
probes were cleaned according to the protocol using the
QIAquick Nucleotide Removal Kit (250), (QIAGEN,
Hilden, Germany). Probe sequences for ApM1 sense and
anti-sense were 5′-GGCCTCTTTTGGCCTCAGTTG
ACTCTCTCTGTGCCTCTGGTTCCAC-3′, and 5′-CC
GGAGAAAACCGGAGTCAACTGAGAGAGACAG
GGAGACCAAGGTG-3′, respectively (MedProbe,
Oslo, Norway). Gamma-actin was used as a positive
control for the presence of mRNA, and to ensure the
quality of the tissues examined. Although gamma-
actin is a housekeeping gene that is widely used as a
marker for adipose tissue-quality and mRNA content,
its expression may differ between individuals and is
significantly up-regulated in obese subjects [19]. The
oligonucleotide probe for gamma-actin was designed as
described previously [19].
In situ hybridization
In brief, the sections were incubated at 42◦C for 15 to
18 hours with 106 cpm of 33P-labeled probe per 100 lL
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of a solution containing 50% formamide, 4 × SSC, 1 ×
Denhardt’s solution, 1% sarcosyl, 0.02 MOL/L sodium
phosphate (NaPO4, pH 7.0), and 10% dextran sulfate
mixed with 500 lg/mL sonicated salmon sperm DNA and
200 mMOL/L dithiothreitol. SSC is a solution of sodium
chloride and sodium citrate, while Denhardt’s solution is
made from Ficoll (10 g), bovine serum albumin (BSA,
10 g), and polyvinylpyrrolidone (10 g) in 500 mL distilled
water. The slides were rinsed in 1 × SSC at 55◦C for 4 × 15
minutes, 1 minute in 60% EtOH, and 1 minute in 99.5%
EtOH. The slides were dried and exposed to Amersham
Hyperfilm b-max x-ray film for 10 days before develop-
ment with Kodak LX24 X-Ray developer and fixation
with Kodak AL4 X-Ray fixer (Rochester, NY, USA).
Quantification of in situ hybridization autoradiographs
Autoradiographic 14C microscale strips ARC-146C
(American Radiolabeled Chemical, Inc., St. Louis, MO,
USA) ranging from 0.017 to 3.0 uCi/g were used as stan-
dards by coexposure with the tissue sections. In the first
experiment, (control patients vs. ESRD MIA), slides
were processed together in triplicate, and were handled as
a single batch through hybridization, washes, autoradio-
graphic exposure, and computerized image analysis. Any
possible batch effect would therefore occur already at
the sectioning stage. A routine quality control histologic
examination was performed and revealed that one tissue
section contained artifacts introduced during the section-
ing procedure. When excluding this tissue section from
the study the difference in expression between ESRD
patients and healthy control patients remained significant
(P < 0.001). In another experiment (ESRD non-MIA vs.
ESRD MIA), slides were processed together in triplicate,
and were handled as a single batch through hybridiza-
tion, washes, autoradiographic exposure, and comput-
erized image analysis. The signals were measured from
high-resolution x-ray films, where sections had been co-
exposed with radioactive standards to linearize the film
response to radiation. Results from repeated measure-
ments were highly reproducible. The semiquantification
of film autoradiograms was carried out by microdensit-
ometry using a Macintosh Quadra 700 computer (Ap-
ple Computer, Inc., Cupertino, CA, USA) equipped with
a Quick Capture frame grabber board (Data Transla-
tion, Marlboro, MA, USA), a Northern Light precision
illuminator (Imaging Research, St. Catherines, Ontario,
Canada), and a Hamamatsu CCD (Hamamatsu, Hama-
matsu City, Japan) camera equipped with a Nikon 55 mm
lens. To process the images, Image software (NIMH,
Bethesda, MD, USA) was used. Each frame was digi-
tized to a 512 × 512 matrix with 256 gray levels for each
picture element. The gray levels, corresponding to the
9 standards lying within the exposure range of the film,
were determined and used in a third-degree polynomial
approximation to construct a gray level to activity trans-
fer function.
Laboratory methods
Serum CRP was measured by nephelometry. Plasma
adiponectin levels were measured in frozen samples
in 6 of the patients by a commercially available high
sensitivity photometric enzyme-linked immunosorbent
assay (ELISA) (Boerhinger Mannheim, Mannheim,
Germany). The plates were read using ELISA VER-
SAmax readerTM (Molecular Devices Corporation, Sun-
nyvale, CA, USA), and the data were analyzed with the
SoftmaxPRO software (Molecular Devices Corpora-
tion).
Statistical analysis
All results were analyzed using StatView for Windows
(SAS, Inc., Cary, NC, USA). For analysis of continuous
data between two groups, the Mann-Whitney U test was
used. Correlations were tested with regression analysis.
A P value < 0.05 was considered significant.
RESULTS
The present results demonstrate a significantly (P =
0.001) lower ApM1 gene expression in 18 ESRD pa-
tients compared with the matched healthy control group
(Fig. 1A). However, no significant difference in ApM1
gene expression was noted between 9 MIA ESRD pa-
tients and 9 non-MIA ESRD patients (Fig. 1B). The sense
background was generally low, with absolute values close
to zero. The mean value for gamma-actin expression was
similar in the control and patient groups (P = 0.44), show-
ing that the down-regulation of the ApM1 gene seen in
ESRD patients is specific for the latter gene. A near signif-
icant inverse (R = −0.77; P = 0.07) correlation between
the ApM1 gene expression levels and plasma adiponectin
levels was noted in 6 of the ESRD patients in which frozen
plasma samples were available (Fig. 2). No significant as-
sociations between the ApM1 gene expression and CVD,
age, and BMI, respectively, were found in this small group
of ESRD patients.
DISCUSSION
The present study shows, for the first time, that ESRD
patients have a low ApM1 gene expression compared
with age-, gender-, and BMI-matched healthy control
patients. On the other hand, no significant difference in
gene expression was noted comparing adipose tissue from
ESRD patients with and without MIA complications.
However, as both ESRD groups had markedly down-
regulated gene expression, small differences in gene
expression may be hard to detect with this technique. Ba-
sically, our finding of a low gene expression of adiponectin
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Fig. 1. Box plot showing the difference
in adiponectin (ApM1) gene expression
between 18 ESRD patients and 9 healthy con-
trol patients (A). Box plot showing no signif-
icant difference in adiponectin (ApM1) gene
expression between 9 ESRD patients with and
9 ESRD patients without MIA complications
(B).
in ESRD corresponds to previously reported data in
other patient groups with increased risk of CVD [18].
In obese postmenopausal women the ApM1 gene ex-
pression was decreased as compared with healthy control
patients, and the expression was significantly associated
to plasma adiponectin levels [20]. A recent study by En-
geli et al [20] showed that the adiponectin gene expression
was inversely associated with higher interleukin (IL)-
6 and hsCRP plasma levels in obese subjects, suggest-
ing that decreased expression of ApM1 may serve as a
marker of increased metabolic and inflammatory risk.
Reduced adiponectin gene expression has also been ob-
served in obese patients with type 2 diabetes compared
with nondiabetic lean and obese subjects [18, 20].
In contrast to findings in other patient groups with in-
creased risk of CVD, circulating plasma adiponectin lev-
els are markedly elevated in ESRD [16, 17]. However,
as Zoccali et al [16] showed that ESRD patients with
lower adiponectin levels (but still higher levels than con-
trol patients) have an increased risk of CVD mortality,
this suggests a vascular protective effect of adiponectin
also in this patient group. The reason(s) why ESRD
patients have increased plasma adiponectin levels are
not clear. However, as the present study demonstrated
lower adiponectin gene expression in adipose tissue
from ESRD patients, it seems reasonable to speculate
that reduced renal clearance and/or other factors associ-
ated with chronic renal disease contribute. Indeed, recent
data suggest that gross proteinuria may be associated
with elevated plasma adiponectin levels in renal pa-
tients [21]. Notably, our finding of a lower expression
of adiponectin mRNA in renal patients corresponds to
previously reported higher plasma adiponectin levels in
ESRD patients compared with control patients [16, 17].
Thus, it could be speculated that elevated plasma levels
of adiponectin caused by renal failure induce a negative
feedback mechanism on the ApM1 gene expression,
resulting in a proportional adjustment of the protein
expression. In fact, we observed a near significant in-
verse correlation between ApM1 gene expression and
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Fig. 2. Relation between adiponectin (ApM1) gene expression and
plasma adiponectin levels in 6 ESRD patients.
adiponectin levels in a subset of 6 ESRD patients, which
supports this hypothesis. Interestingly, our results seem
identical to those previously obtained for leptin—another
adipocytokine with elevated circulating plasma levels,
and low gene expression, in ESRD [22]. Clearly, fur-
ther studies are needed to investigate if the high circu-
lating adiponectin levels seen in ESRD may reflect intact
(or less active) adiponectin and/or poor binding to the
adiponectin receptors, which were recently cloned [23].
Also, as proinflammatory cytokines, such as IL-6 and tu-
mor necrosis factor (TNF)-a, have been shown to down-
regulate adiponectin mRNA in fat tissue in vitro [24],
further studies are needed to investigate if the observed
down-regulation of ApM1 gene expression is related to
inflammation, a common feature of ESRD [2].
Some limitations of the present study should be con-
sidered. First, as the number of patients was limited our
results must be confirmed in larger studies, and the effects
of adiponectin administration on gene expression should
be evaluated in vitro. Second, as plasma adiponectin lev-
els were available only in 6 patients the observed relation
between circulating adiponectin levels and gene expres-
sion must be interpreted with caution. However, because
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Table 1. Clinical characteristics of the three groups
Healthy ESRD ESRD P
subjects (MIA) (non-MIA) value
Number 9 9 9
Age years 59 ± 11 60 ± 8 55 ± 9 NS
Males 78% 78% 78% NS
BMI kg/m2 24 ± 6 24 ± 2 24 ± 6 NS
Glomerular filtration ND 6 ± 1 6 ± 1 NS
rate mL/min
MIA–complications
Malnutrition (SGA >1) 0% 89% 0%
Inflammation (CRP ND 67% 22%
≥10 mg/L)
Atherosclerotic 0% 78% 0%
cardiovascular disease
Coronary heart disease 0% 22% 0%
Cerebrovascular disease 0% 34% 0%
Peripheral vascular disease 0% 22% 0%
ND, not determined; NS, not significant.
this apparently linear relationship is intriguing, and may
reflect a biologically relevant feed-back mechanism sim-
ilar to the one observed for leptin in ESRD, this pre-
liminary observation should stimulate further research.
Third, as the classification of CVD was made only on the
basis of clinically manifest events, the true prevalence of
atherosclerotic vascular disease may have been underes-
timated.
CONCLUSION
The present study demonstrates a significant down-
regulation of the ApM1 gene in fat tissue from ESRD
patients compared with control patients. Because the
down-regulation of the gene expression seems to be
proportional to elevated plasma levels of adiponectin,
we propose that a negative feedback mechanism down-
regulates the ApM1 gene expression in ESRD patients.
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